Medincell Resumes Trading After Suspension Amid Pending Announcement

  • Trading in Medincell shares on Euronext Paris was suspended at 9:00 a.m. CEST on October 9, 2026, at the company's request.
  • Trading resumed at 2:45 p.m. CEST the same day, following the pending publication of a press release.
  • Medincell's BEPO® technology is licensed to Teva as SteadyTeq™, with two FDA-approved treatments (UZEDY® and WELTRUZA™) marketed by Teva.
  • Olanzapine LAI received FDA approval in October 2026, with a U.S. launch planned in Q4 2026 and a European MAA accepted by EMA in May 2026.

Medincell's resumption of trading follows a brief suspension, highlighting the strategic importance of its BEPO® technology in the biopharmaceutical sector. The company's focus on long-acting injectables aligns with industry trends toward improved patient adherence and reduced environmental impact. With Teva as a key partner, Medincell is positioned to capitalize on regulatory milestones and commercial launches, though execution risks remain.

Regulatory Momentum
The pace at which Medincell secures additional regulatory approvals for its pipeline, particularly in Europe, will determine its commercial expansion.
Commercial Execution
Whether Teva can effectively launch and market WELTRUZA™ in the U.S. and Europe, given its existing partnership with Medincell.
Market Reaction
How investors interpret the resumption of trading and any forthcoming announcements, particularly in light of the company's strategic positioning in long-acting injectables.